insulin detemir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4985 169148-63-4

Description:

MoleculeDescription

Synonyms:

  • insulin detemir
  • levemir
  • insulin detemir recombinant
  • insulin detemir [rDNA origin]
  • NN304
  • NN 304
  • NN-304
A recombinant long-acting insulin and hypoglycemic agent in which a MYRISTIC ACID is conjugated to a LYSINE at position B29. It is used to manage BLOOD GLUCOSE levels in patients with DIABETES MELLITUS.
  • Molecular weight: 5916.89
  • Formula: C267H402N64O76S6
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 2252.82
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
40 U P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
June 1, 2004 EMA
June 16, 2005 FDA NOVO NORDISK INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood glucose increased 658.68 12.64 399 21352 70925 50512448
Hypoglycaemia 507.84 12.64 305 21446 53276 50530097
Diabetic ketoacidosis 358.58 12.64 168 21583 17704 50565669
Blood glucose decreased 194.09 12.64 112 21639 18099 50565274
Hyperglycaemia 176.23 12.64 137 21614 36268 50547105
Lactic acidosis 164.66 12.64 127 21624 33228 50550145
Diabetes mellitus inadequate control 151.23 12.64 85 21666 13060 50570313
Glycosylated haemoglobin increased 134.13 12.64 73 21678 10533 50572840
Blood glucose fluctuation 111.92 12.64 48 21703 4098 50579275
Ketoacidosis 98.29 12.64 43 21708 3852 50579521
Gangrene 96.79 12.64 45 21706 4647 50578726
Exposure during pregnancy 94.61 12.64 179 21572 120836 50462537
Hypoglycaemic unconsciousness 80.68 12.64 24 21727 698 50582675
Acute kidney injury 79.81 12.64 247 21504 227811 50355562
Drug ineffective 70.87 12.64 155 21596 819178 49764195
Arterial occlusive disease 68.97 12.64 36 21715 4772 50578601
Diabetic retinopathy 67.71 12.64 28 21723 2182 50581191
Injection site mass 61.04 12.64 52 21699 15628 50567745
Drug intolerance 57.61 12.64 12 21739 219092 50364281
Hypoglycaemic coma 56.42 12.64 25 21726 2308 50581065
Insulin resistance 51.70 12.64 17 21734 691 50582682
Blood glucose abnormal 48.08 12.64 32 21719 6640 50576733
Treatment failure 47.29 12.64 3 21748 137634 50445739
Premature delivery 46.37 12.64 54 21697 23609 50559764
Anti-insulin antibody positive 45.37 12.64 10 21741 82 50583291
Pancreatitis 42.23 12.64 70 21681 42544 50540829
Alopecia 41.71 12.64 27 21724 245020 50338353
Systemic infection 41.28 12.64 20 21731 2263 50581110
Infusion related reaction 41.17 12.64 11 21740 169546 50413827
Infective pulmonary exacerbation of cystic fibrosis 40.94 12.64 31 21720 7878 50575495
Visceral congestion 37.61 12.64 11 21740 301 50583072
Angina pectoris 37.35 12.64 51 21700 26137 50557236
Injection site urticaria 36.66 12.64 35 21716 12182 50571191
Joint swelling 35.40 12.64 32 21719 245254 50338119
Completed suicide 35.10 12.64 7 21744 131882 50451491
Anuria 33.34 12.64 32 21719 11212 50572161
Hypoglycaemic seizure 33.29 12.64 11 21740 454 50582919
Hypoglycaemia neonatal 32.97 12.64 13 21738 895 50582478
Pre-eclampsia 31.96 12.64 27 21724 8017 50575356
Injection site pruritus 29.34 12.64 58 21693 40353 50543020
Arthropathy 28.81 12.64 16 21735 157890 50425483
Injection site erythema 28.79 12.64 84 21667 74852 50508521
Blood ketone body 27.35 12.64 6 21745 48 50583325
Foetal exposure during pregnancy 27.18 12.64 45 21706 27314 50556059
Diabetic neuropathy 25.34 12.64 17 21734 3574 50579799
General physical health deterioration 24.83 12.64 124 21627 142310 50441063
Therapeutic product effect decreased 24.51 12.64 14 21737 136036 50447337
Pain 24.17 12.64 148 21603 578755 50004618
Rhonchi 24.06 12.64 14 21737 2293 50581080
Anti-insulin antibody 23.64 12.64 5 21746 33 50583340
Hypoglycaemia unawareness 23.11 12.64 6 21745 104 50583269
Discomfort 22.82 12.64 9 21742 108371 50475002
Hepatic enzyme increased 22.20 12.64 16 21735 137364 50446009
Gestational hypertension 22.17 12.64 13 21738 2160 50581213
Pancreatitis acute 22.10 12.64 38 21713 23774 50559599
Musculoskeletal stiffness 22.05 12.64 14 21737 128467 50454906
Vomiting 21.63 12.64 297 21454 460461 50122912
Treatment noncompliance 21.55 12.64 43 21708 30107 50553266
Anti-insulin antibody increased 21.36 12.64 5 21746 55 50583318
Premature baby 20.73 12.64 32 21719 18305 50565068
Hyperkalaemia 20.51 12.64 56 21695 48033 50535340
Product administration error 20.37 12.64 33 21718 19666 50563707
Neonatal anoxia 20.26 12.64 3 21748 0 50583373
Increased insulin requirement 20.25 12.64 5 21746 70 50583303
Pallor 20.20 12.64 36 21715 23163 50560210
Product use issue 19.81 12.64 21 21730 149454 50433919
Diabetic nephropathy 19.13 12.64 10 21741 1329 50582044
Cataract 19.11 12.64 54 21697 47246 50536127
Altered state of consciousness 19.08 12.64 34 21717 21876 50561497
Infection 19.05 12.64 28 21723 172926 50410447
Arthralgia 18.88 12.64 111 21640 438591 50144782
Gastric disorder 18.61 12.64 40 21711 29508 50553865
Cerebrovascular accident 18.35 12.64 85 21666 94595 50488778
Injection site rash 17.97 12.64 28 21723 16149 50567224
Acute myocardial infarction 17.72 12.64 39 21712 29234 50554139
Extradural haematoma 17.54 12.64 10 21741 1577 50581796
Cardiac death 17.48 12.64 7 21744 502 50582871
Abdominal discomfort 17.35 12.64 47 21704 231594 50351779
Asphyxia 17.15 12.64 16 21735 5411 50577962
Injection site nodule 17.06 12.64 13 21738 3335 50580038
Diabetic retinal oedema 16.68 12.64 6 21745 320 50583053
Multiple lentigines syndrome 16.56 12.64 5 21746 153 50583220
Fall 16.55 12.64 218 21533 334714 50248659
Febrile neutropenia 16.27 12.64 11 21740 97656 50485717
Diabetes mellitus 16.06 12.64 52 21699 48981 50534392
Dehydration 15.84 12.64 116 21635 152333 50431040
Therapeutic product effect incomplete 15.66 12.64 10 21741 91505 50491868
Anaemia 15.38 12.64 171 21580 252285 50331088
Metabolic acidosis 15.36 12.64 44 21707 38781 50544592
Pancreatic carcinoma 15.32 12.64 16 21735 6198 50577175
Neutropenia 15.29 12.64 25 21726 147940 50435433
Blood insulin decreased 15.24 12.64 3 21748 13 50583360
Diabetic gangrene 15.06 12.64 3 21748 14 50583359
Urogenital haemorrhage 14.43 12.64 5 21746 239 50583134
Impaired healing 14.35 12.64 6 21745 69780 50513593
Lower respiratory tract infection 14.22 12.64 12 21739 95189 50488184
Renal failure 13.99 12.64 86 21665 106547 50476826
Macular oedema 13.98 12.64 12 21739 3642 50579731
Wrong product administered 13.57 12.64 14 21737 5346 50578027
Paraplegia 13.55 12.64 10 21741 2444 50580929
Shock hypoglycaemic 13.52 12.64 4 21747 114 50583259
Cataract subcapsular 13.49 12.64 6 21745 559 50582814
Cystoid macular oedema 13.31 12.64 8 21743 1391 50581982
Mycobacterium avium complex infection 13.28 12.64 10 21741 2520 50580853
Drug level above therapeutic 13.25 12.64 12 21739 3908 50579465
Diabetic metabolic decompensation 12.89 12.64 8 21743 1472 50581901
Decreased insulin requirement 12.88 12.64 4 21747 135 50583238
Vanishing bile duct syndrome 12.80 12.64 6 21745 631 50582742
White blood cell count decreased 12.74 12.64 19 21732 116703 50466670

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 423.96 12.74 289 16305 48057 29509876
Blood glucose increased 298.21 12.74 254 16340 58730 29499203
Diabetic ketoacidosis 171.96 12.74 109 16485 15964 29541969
Diabetes mellitus inadequate control 146.79 12.74 89 16505 12045 29545888
Blood glucose decreased 102.74 12.74 71 16523 11998 29545935
Blood glucose fluctuation 84.53 12.74 41 16553 3556 29554377
Hypoglycaemic unconsciousness 65.11 12.74 22 16572 741 29557192
Hypoglycaemic coma 61.12 12.74 28 16566 2135 29555798
Anti-insulin antibody positive 58.85 12.74 15 16579 181 29557752
Foetal disorder 56.82 12.74 20 16574 763 29557170
General physical health deterioration 56.13 12.74 155 16439 102702 29455231
Hyperglycaemia 53.36 12.74 80 16514 34207 29523726
Toxicity to various agents 52.73 12.74 16 16578 173645 29384288
Glycosylated haemoglobin increased 52.44 12.74 43 16551 9383 29548550
Pancreatic carcinoma metastatic 49.25 12.74 26 16568 2695 29555238
Neutropenia neonatal 48.51 12.74 17 16577 640 29557293
Premature baby 48.49 12.74 54 16540 17226 29540707
Injection site mass 39.29 12.74 29 16565 5426 29552507
Hypoglycaemic seizure 39.02 12.74 12 16582 297 29557636
Blood glucose abnormal 36.56 12.74 27 16567 5056 29552877
Drug abuse 33.76 12.74 3 16591 79880 29478053
Injection site erythema 33.10 12.74 40 16554 13916 29544017
Ketoacidosis 32.35 12.74 22 16572 3617 29554316
Acute kidney injury 32.02 12.74 256 16338 265011 29292922
Injection site pruritus 31.11 12.74 26 16568 5823 29552110
Injection site urticaria 31.03 12.74 16 16578 1580 29556353
Low birth weight baby 30.33 12.74 27 16567 6581 29551352
Pancreatitis chronic 30.11 12.74 17 16577 2011 29555922
Diabetic metabolic decompensation 29.87 12.74 15 16579 1401 29556532
Pancreatitis 29.57 12.74 62 16532 34452 29523481
Product prescribing error 29.47 12.74 43 16551 17933 29540000
Vomiting projectile 27.69 12.74 11 16583 589 29557344
Foetal exposure during pregnancy 25.77 12.74 58 16536 33809 29524124
Diabetic neuropathy 24.91 12.74 19 16575 3734 29554199
Pancreatic carcinoma 24.77 12.74 25 16569 7125 29550808
Completed suicide 24.47 12.74 10 16584 90236 29467697
Hypoglycaemia unawareness 21.42 12.74 6 16588 106 29557827
Adenocarcinoma pancreas 20.14 12.74 11 16583 1220 29556713
Exposure to communicable disease 20.09 12.74 6 16588 134 29557799
Febrile neutropenia 20.09 12.74 20 16574 112220 29445713
Laryngeal leukoplakia 20.04 12.74 5 16589 55 29557878
Diabetic retinopathy 20.00 12.74 12 16582 1590 29556343
Anaemia vitamin B12 deficiency 19.54 12.74 7 16587 281 29557652
Diabetic foot 18.76 12.74 13 16581 2203 29555730
Injection site pain 18.75 12.74 50 16544 32396 29525537
Dehydration 18.57 12.74 119 16475 114629 29443304
Oedema peripheral 18.39 12.74 110 16484 103447 29454486
Device failure 17.48 12.74 12 16582 2004 29555929
Injection site rash 17.23 12.74 15 16579 3549 29554384
Diabetes mellitus 16.91 12.74 55 16539 39776 29518157
Drug ineffective 16.90 12.74 127 16467 363043 29194890
Infective pulmonary exacerbation of cystic fibrosis 16.65 12.74 19 16575 6217 29551716
Pneumobilia 16.11 12.74 4 16590 43 29557890
Shock haemorrhagic 15.87 12.74 23 16571 9528 29548405
Injection site nodule 15.78 12.74 10 16584 1460 29556473
Diabetic coma 15.69 12.74 8 16586 772 29557161
Infusion related reaction 15.32 12.74 3 16591 43883 29514050
Funguria 15.14 12.74 4 16590 56 29557877
Product monitoring error 14.57 12.74 12 16582 2633 29555300
Diabetic foot infection 14.39 12.74 7 16587 610 29557323
Product quality issue 14.13 12.74 29 16565 15866 29542067
Urogenital infection fungal 14.09 12.74 3 16591 15 29557918
Lipohypertrophy 13.68 12.74 5 16589 213 29557720
Pancreatitis necrotising 13.67 12.74 11 16583 2336 29555597
Injection site irritation 13.41 12.74 8 16586 1049 29556884
Limb injury 13.37 12.74 21 16573 9334 29548599
Acute febrile neutrophilic dermatosis 13.29 12.74 8 16586 1066 29556867
Shock hypoglycaemic 13.05 12.74 4 16590 98 29557835
Injection site ulcer 13.01 12.74 5 16589 245 29557688

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 758.46 11.78 497 30849 89395 64377991
Blood glucose increased 590.32 11.78 441 30905 97632 64369754
Diabetic ketoacidosis 434.79 11.78 235 31111 29610 64437776
Diabetes mellitus inadequate control 245.61 11.78 144 31202 21177 64446209
Hyperglycaemia 185.70 11.78 186 31160 60782 64406604
Blood glucose decreased 182.77 11.78 123 31223 23000 64444386
Lactic acidosis 137.10 11.78 159 31187 61251 64406135
Blood glucose fluctuation 134.02 11.78 63 31283 5892 64461494
Ketoacidosis 119.67 11.78 61 31285 6802 64460584
Hypoglycaemic unconsciousness 115.44 11.78 36 31310 1085 64466301
Acute kidney injury 113.61 11.78 475 30871 448765 64018621
Glycosylated haemoglobin increased 107.31 11.78 77 31269 15942 64451444
Gangrene 90.95 11.78 52 31294 7286 64460100
Anti-insulin antibody positive 89.49 11.78 22 31324 265 64467121
Hypoglycaemic coma 89.40 11.78 43 31303 4231 64463155
General physical health deterioration 83.22 11.78 253 31093 204172 64263214
Diabetic retinopathy 79.57 11.78 35 31311 2804 64464582
Drug ineffective 69.21 11.78 196 31150 840051 63627335
Completed suicide 62.49 11.78 16 31330 224398 64242988
Injection site mass 60.62 11.78 57 31289 17213 64450173
Blood glucose abnormal 55.51 11.78 41 31305 8872 64458514
Arterial occlusive disease 52.20 11.78 36 31310 6997 64460389
Exposure during pregnancy 52.07 11.78 116 31230 77559 64389827
Pancreatitis 51.71 11.78 99 31247 59508 64407878
Infective pulmonary exacerbation of cystic fibrosis 49.40 11.78 43 31303 11753 64455633
Hypoglycaemic seizure 48.30 11.78 17 31329 751 64466635
Infusion related reaction 45.25 11.78 12 31334 164455 64302931
Pancreatic carcinoma metastatic 44.05 11.78 25 31321 3453 64463933
Diabetic neuropathy 42.34 11.78 29 31317 5572 64461814
Injection site urticaria 41.36 11.78 38 31308 11143 64456243
Drug intolerance 39.57 11.78 21 31325 187971 64279415
Insulin resistance 38.92 11.78 16 31330 1084 64466302
Product prescribing error 37.49 11.78 64 31282 35205 64432181
Toxicity to various agents 36.72 11.78 76 31270 363437 64103949
Drug abuse 35.77 11.78 10 31336 132364 64335022
Diabetic metabolic decompensation 35.61 11.78 20 31326 2708 64464678
Treatment failure 35.16 11.78 7 31339 116809 64350577
Joint swelling 34.84 11.78 32 31314 215350 64252036
Pancreatitis chronic 33.02 11.78 21 31325 3565 64463821
Hypoglycaemia unawareness 32.89 11.78 9 31337 169 64467217
Injection site pruritus 30.58 11.78 61 31285 37765 64429621
Febrile neutropenia 30.20 11.78 28 31318 187629 64279757
Anti-insulin antibody 29.84 11.78 7 31339 68 64467318
Dehydration 29.32 11.78 193 31153 216570 64250816
Injection site erythema 28.15 11.78 87 31259 70713 64396673
Pancreatitis acute 27.59 11.78 63 31283 42792 64424594
Contraindicated product administered 27.58 11.78 9 31337 107820 64359566
Injection site nodule 27.48 11.78 18 31328 3212 64464174
Systemic infection 27.18 11.78 20 31326 4301 64463085
Angina pectoris 26.54 11.78 64 31282 45017 64422369
Anti-insulin antibody increased 26.52 11.78 7 31339 114 64467272
Visceral congestion 25.87 11.78 11 31335 811 64466575
Anaemia vitamin B12 deficiency 25.86 11.78 10 31336 577 64466809
Blood ketone body 25.55 11.78 7 31339 132 64467254
Hyperkalaemia 25.45 11.78 107 31239 101022 64366364
Product quality issue 25.23 11.78 49 31297 29750 64437636
Adenocarcinoma pancreas 25.18 11.78 14 31332 1859 64465527
Diabetes mellitus 23.98 11.78 79 31267 66395 64400991
Anuria 23.66 11.78 37 31309 18927 64448459
Gastric disorder 23.50 11.78 47 31299 29150 64438236
Arthropathy 23.33 11.78 15 31331 120952 64346434
Cataract 23.24 11.78 66 31280 51196 64416190
Anaemia 22.11 11.78 281 31065 378399 64088987
Vomiting 22.03 11.78 383 30963 550734 63916652
Alopecia 21.95 11.78 29 31317 165661 64301725
Euglycaemic diabetic ketoacidosis 21.21 11.78 19 31327 5391 64461995
Neutropenia 21.02 11.78 54 31292 239570 64227816
Laryngeal leukoplakia 20.67 11.78 5 31341 56 64467330
Device failure 20.38 11.78 19 31327 5673 64461713
Increased insulin requirement 20.08 11.78 6 31340 156 64467230
Diabetic coma 19.56 11.78 10 31336 1121 64466265
Rhonchi 19.50 11.78 15 31331 3448 64463938
Glossodynia 19.21 11.78 4 31342 64692 64402694
Diabetic foot 19.11 11.78 14 31332 2991 64464395
Vomiting projectile 18.97 11.78 11 31335 1582 64465804
Gestational hypertension 18.42 11.78 11 31335 1670 64465716
Infection 18.34 11.78 39 31307 184841 64282545
Pericarditis 18.28 11.78 4 31342 62512 64404874
Accidental underdose 18.03 11.78 8 31338 654 64466732
Musculoskeletal stiffness 17.97 11.78 20 31326 123186 64344200
Treatment noncompliance 17.81 11.78 54 31292 43428 64423958
Premature delivery 17.51 11.78 32 31314 18557 64448829
Injection site rash 17.30 11.78 29 31317 15713 64451673
Pre-eclampsia 17.12 11.78 18 31328 6213 64461173
Pancreatic carcinoma 16.96 11.78 23 31323 10350 64457036
Visual impairment 16.81 11.78 76 31270 74001 64393385
Therapeutic product effect decreased 16.52 11.78 19 31327 115332 64352054
Arthralgia 16.33 11.78 137 31209 442123 64025263
Metabolic acidosis 16.25 11.78 73 31273 70885 64396501
Diabetic nephropathy 16.06 11.78 12 31334 2642 64464744
Injection site irritation 16.02 11.78 13 31333 3227 64464159
Product administration error 16.01 11.78 39 31307 27604 64439782
Nonreassuring foetal heart rate pattern 15.74 11.78 3 31343 9 64467377
Diabetic gangrene 15.66 11.78 5 31341 163 64467223
Diabetic retinal oedema 15.60 11.78 6 31340 341 64467045
Syncope 15.40 11.78 130 31216 157505 64309881
Lower respiratory tract infection 15.35 11.78 14 31332 94600 64372786
Duodenal neoplasm 15.34 11.78 4 31342 62 64467324
Product dispensing error 15.21 11.78 23 31323 11427 64455959
Hepatic enzyme increased 15.01 11.78 25 31321 129918 64337468
Cellulitis 14.91 11.78 87 31259 93570 64373816
Multiple lentigines syndrome 14.80 11.78 5 31341 195 64467191
Urogenital infection fungal 14.52 11.78 3 31343 15 64467371
Discomfort 14.31 11.78 11 31335 80867 64386519
White blood cell count decreased 14.27 11.78 35 31311 157802 64309584
Dizziness 14.07 11.78 290 31056 429873 64037513
Dyspnoea 13.98 11.78 452 30894 718222 63749164
Blood insulin decreased 13.92 11.78 3 31343 19 64467367
Device malfunction 13.73 11.78 28 31318 17605 64449781
Off label use 13.63 11.78 221 31125 632585 63834801
Chronic kidney disease 13.58 11.78 60 31286 57859 64409527
Injection site pain 13.15 11.78 96 31250 111312 64356074
Type 1 diabetes mellitus 13.10 11.78 15 31331 5690 64461696
Pallor 13.02 11.78 45 31301 38736 64428650
Asthenia 12.85 11.78 285 31061 427759 64039627
Insulin-requiring type 2 diabetes mellitus 12.07 11.78 4 31342 147 64467239
Decreased insulin requirement 12.07 11.78 4 31342 147 64467239
Pancreatitis necrotising 12.03 11.78 11 31335 3206 64464180
Fall 12.03 11.78 276 31070 416550 64050836
Acute myocardial infarction 11.91 11.78 66 31280 69652 64397734
Diabetic ketosis 11.90 11.78 5 31341 358 64467028
Injection site ulcer 11.83 11.78 6 31340 661 64466725
Oedema peripheral 11.79 11.78 155 31191 210162 64257224

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10AE05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for injection, long-acting
FDA CS M0011417 Insulin
FDA Chemical/Ingredient N0000004931 Insulin
FDA EPC N0000175453 Insulin Analog
MeSH PA D007004 Hypoglycemic Agents
CHEBI has role CHEBI:35526 antidiabetic
FDA EPC N0000175944 Insulin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus indication 73211009 DOID:9351




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Insulin receptor Kinase AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
D04539 KEGG_DRUG
4017559 VANDF
4017569 VANDF
4019786 VANDF
CHEBI:5931 CHEBI
CHEMBL2104391 ChEMBL_ID
7735 INN_ID
DB01307 DRUGBANK_ID
4FT78T86XV UNII
16137271 PUBCHEM_CID
118984375 PUBCHEM_CID
DB00030 DRUGBANK_ID
139825 RXNORM
19234 MMSL
4885 MMSL
4886 MMSL
72333 MMSL
d00262 MMSL
d04369 MMSL
d05436 MMSL
126210001 SNOMEDCT_US
414515005 SNOMEDCT_US
414518007 SNOMEDCT_US
417423002 SNOMEDCT_US
420609005 SNOMEDCT_US
96367001 SNOMEDCT_US
D000069057 MESH_DESCRIPTOR_UI
C0537270 UMLSCUI
C0795635 UMLSCUI
5186 INN_ID
000869 NDDF
000870 NDDF
006518 NDDF
010059 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 0169-3687 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 0169-6438 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 50090-1276 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 50090-1276 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 50090-1475 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 50090-1475 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 50090-4501 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 54868-5883 INJECTION, SOLUTION 14.20 mg SUBCUTANEOUS NDA 26 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 68258-8977 IMPLANT 14.20 mg SOFT TISSUE NDA 26 sections
Levemir HUMAN PRESCRIPTION DRUG LABEL 1 70518-1462 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections